Chemomab (CMMB) CEO adds 9,804 ADS in May 29 purchases

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. Chief Executive Officer Mor George Adi reported buying American Depositary Shares on the open market. On May 29, 2026, he purchased 4,926 ADS at $2.08 and 4,878 ADS at $2.05, for a total of 9,804 ADS. Additional J-coded entries reflect RSU positions that, according to the footnotes, involved no transaction and are included for informational purposes only, with vesting running in quarterly installments through October 1, 2028 and April 10, 2029.

Insider Trade Summary

Net Buyer: 9,804 shares ($20,246)

Net Buy 4 txns

Insider Mor George Adi

Role Chief Executive Officer

Bought 9,804 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	American Depositary Shares	4,878	$2.05	$10K
Purchase	American Depositary Shares	4,926	$2.08	$10K
Other	American Depositary Shares	31,712	$0.00	--
Other	American Depositary Shares	18,750	$0.00	--

Holdings After Transaction: American Depositary Shares — 134,205 shares (Direct, null)

Footnotes (1)

No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.

Key Figures

Open-market purchase 1: 4,926 ADS at $2.08 Open-market purchase 2: 4,878 ADS at $2.05 Total ADS bought: 9,804 ADS +2 more

5 metrics

Open-market purchase 1 4,926 ADS at $2.08 Non-derivative purchase on May 29, 2026

Open-market purchase 2 4,878 ADS at $2.05 Non-derivative purchase on May 29, 2026

Total ADS bought 9,804 ADS Net buy shares from transaction summary

RSU block 1 18,750 ADS-equivalent RSUs Grant reported with vesting through October 1, 2028

RSU block 2 31,712 ADS-equivalent RSUs Grant reported with vesting through April 10, 2029

Key Terms

American Depositary Shares, restricted share units ("RSUs"), open-market purchase, Other acquisition or disposition, +1 more

5 terms

American Depositary Shares financial

"The American Depositary Shares reported in this row consist of restricted share units"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Other acquisition or disposition financial

"transaction_code_description": "Other acquisition or disposition""

Form 4 regulatory

"they are being included in this Form 4 for informational purposes only"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 07:33 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mor George Adi

(Last)

(First)

(Middle)

C/O CHEMOMAB THERAPEUTICS LTD.

10 HABARZEL ST., BUILDING C, 10TH FLOOR

(Street)

TEL AVIV

615810

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
American Depositary Shares	05/29/2026		P		4,878	D	$2.05	134,205	D
American Depositary Shares	05/29/2026		P		4,926	D	$2.08	139,131	D
American Depositary Shares	05/29/2026		J		31,712⁽²⁾	D	⁽¹⁾	31,712	D
American Depositary Shares	05/29/2026		J		18,750⁽³⁾	D	⁽¹⁾	18,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

2. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.

3. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.

	/s/ Adi Mor George	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Chemomab (CMMB) report for its CEO?

Chemomab reported that CEO Mor George Adi bought ADS in the open market. On May 29, 2026, he acquired 4,926 ADS at $2.08 and 4,878 ADS at $2.05, totaling 9,804 ADS in direct purchases.

Were the Chemomab (CMMB) CEO’s Form 4 transactions open-market buys?

Yes. The Form 4 identifies two transactions with code P, described as open-market or private purchases. The CEO bought 4,926 ADS at $2.08 and 4,878 ADS at $2.05 per share, both dated May 29, 2026.

What does the J code mean in the Chemomab (CMMB) CEO Form 4 filing?

The J-coded entries are labeled as other acquisitions or dispositions. A footnote states no transaction was effected for these securities and they are included for informational purposes only, reflecting RSU positions rather than new market trades.

How many Chemomab (CMMB) ADS did the CEO buy according to this Form 4?

The CEO’s net open-market buying totaled 9,804 ADS. This comes from two purchases: 4,926 ADS at $2.08 per share and 4,878 ADS at $2.05 per share, all on May 29, 2026, as summarized in the filing’s transaction data.

What RSU grants to the Chemomab (CMMB) CEO are described in the Form 4 footnotes?

Footnotes describe RSUs granted on November 18, 2024 and July 1, 2025. The 2024 grant vests 25% on October 1, 2025, then 6.25% quarterly until October 1, 2028, while the 2025 grant follows a similar schedule through April 10, 2029.

Did the Chemomab (CMMB) CEO’s RSU positions involve new trades in this Form 4?

No. A footnote explicitly states no transaction was effected regarding the RSU-related ADS and that they are included for informational purposes only. These entries outline existing RSU grants and vesting schedules rather than new market activity.